Exploring the Interconnection between Depression and Anxiety: Theories, Herbal Treatments, and Therapeutic Approaches

Pardeep Kaur[1st], Jasleen Kaur[2nd], Sahil Punia 3[rd], Diksha Sharma[4th], Anchal Dhawan[5th]

Jasleen Kaur, Assistant Professor, Rayat Bahra University, Mohali, Punjab

Akal College of Pharmacy& Technical education1[st], Rayat Bahra University2[nd],3[rd],4[th],5[th]

ABSTRACT

Pharmacological therapies for anxiety-related conditions are more secure and bearable today than they were a generation ago. Despite a deeper comprehension of the pathogenesis feeling uneasy, therapy efficacy additionally longevity have not increased in most patients. Furthermore, despite billions of dollars expended in drug development research, breakthrough medications have yet to enter the market. After examining the literature on existing treatments, we conclude that additional research on the underlying reasons of incomplete treatment response, as well as the contrasting efficacy of medication combinations and sequencing, will promote evidence-based practice. The continuous development of medications centered on distinct neurorecseptor and the therapeutic modification of fear-related memory.in this essays we have discuss

INTRODUCTION

In his renowned work "The Meaning of Anxiety," he discusses the importance of the anxiety problem in contemporary literature, music, art, and religion in addition to psychiatry, psychoanalysis, and psychology. Fear and anxiety have long been regarded as the most fundamental human emotions. Cohen claims that there is no question about how fear was depicted in ancient Egyptian hieroglyphs. A lecturer at Princeton University's Department of Oriental Studies named James Kretek observed that the mediaeval Arab philosopher Ala ibn Hazm of Cordova wrote extensively about worry. In his dissertation "A Philosophy of Character and Conduct" from the eleventh century, Ibn Hazm unequivocally asserts that worry is a condition that all people experience. Anxiety disorders are of the most common mental illnesses in children The US of America (US), for all time prevalence of pediatric anxiety of roughly 15-20%. Children who struggle with anxiety are more prone to experience various anxiety disorders, depression, drug use, and academic challenges.3–8 Paediatric anxiety disorders are likely to be accompanied by somatic symptoms such headaches, gaseousness, and sleeplessness. Uncontrolled anxiety has a lasting impact. The management of symptoms, improvement of life quality, and decline in the persistence of fear throughout adolescence and beyond depend on the early detection and therapy for disorders of anxiety.

Numerous disorders of anxiety exist, and they can be extremely crippling. Generalized anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder, panic disorder, and social anxiety are the five main subtypes that can be distinguished by their unique symptoms and thought processes. In order to address anxiety problems, all pharmaceuticals additionally psychosocial interventions Are useful. Self-reported anxiety and fear symptoms, increased stress reactivity to hostile stimuli, attention prejudices with clear and present danger-relevant stimuli and risk-based appraisals of uncertain stimuli, and increased amygdala reactions to threat-relevant stimuli are all characteristics of anxiety and fear, according to the data.

HOW COMMON IS ANXIETY

Types	Percentage of population in the USA
Fears (such as a fear of heights)	8.7%
Anxiety in society	6.7%
PTSD, or condition resulting from extreme stress	3.4%
fear disorders in general (GAD)	3%
Anxiety disorders	2.6%
OCD, or obsessive-compulsive disorder	1%

We know a great deal about anxiety disorders because they are so prevalent. Although anxiety is difficult to live with, it is treatable.

DEPRESSION

Depression is a mental health condition marked by ongoing melancholy and a decline in interest in hobbies and interests that you used to find enjoyable. It could also be difficult to think, remember things, eat, and sleep. It's common to have sadness or regret over trying circumstances in life, such as job loss or divorce. Melancholy differs from depression in that it is accompanied by other symptoms and persists for a minimum of two weeks.

Depressive illnesses come in a variety of forms. It's common to refer to clinical depression, additionally referred to as major depression, as "depression." Which is the most harsh kind of depression? Depression may worsen and last longer if treatment is not received. In severe circumstances, self-harm or suicide may result. Fortunately, most therapies result in a significant reduction of symptoms.

HOW RARE DEPRESSION IS

Depression is rather typical. Research indicates that 7% of Americans experience depression each year. More over 16% of American adults, or around 1 in 6 people, may experience depression at some point in their lives. Researchers claim that these numbers may be underestimated because many people avoid seeking medical attention. Attention for their signs of sadness and go undetected. In the US, 4.4% of children and adolescents are depressed.

EPIDEMOLOGY OF BOTH

In Australia, 6.2% of cases are associated with depressive disorders and 14.4% with anxiety disorders. Research demonstrates that 39% of people with generalized GAD, or anxiety disorder, also match the requirements for melancholy.

CRITICAL RISK FACTOR FOR ANXIETY IN DEPRESSION AND DEPRESSION IN ANXIETY

- As much as 25% of patients in general practice has co-occurring disorders of anxiety and sadness.
- In 84% of cases, there are signs of depression. Ninety percent of people depression is also present in those with anxiety problems.
- At first, the Symptomatology could appear ambiguous and widespread. A thorough medical history and assessment should be performed, along with any required investigations, in order to establish the diagnosis.
- Rating scales can be used to determine the intensity of a problem and monitor the efficacy of the medical intervention after a diagnosis has been made.
- Treatment is necessary for both the specific anxiety condition and the depressive disorder.
- Cognitive behavior therapy and antidepressants, which are occasionally paired with antipsychotics, are psychological treatments that have been demonstrated to be successful in treating depression and anxiety.
- While benzodiazepines do not cure depression, they can help with anxiety and insomnia. Dependency and being cut off from them can be problems for some people, which could get worse
- Even though there are therapies for depression and anxiety, 40% of patients don't ask for assistance, and of those who do, less than half get quality therapy.
- Comorbid depression affects up to 89% of persons Having diseases of anxiety, and severe signs of anxiousness are present in 85% of individuals with depression

The Anxiety and depression symptoms have been referred to as a "mixed anxiety-depressive disorder"(4), However, it's still important to treat each group of symptoms independently. They can affect people of all ages, but just 7.4% of elderly fulfilled the standards for a lifelong severe depression illness within the absence of a 12-month history of GAD. Substance use disorders are linked to anxiety and depression (5, 6), and 7% of individuals affected have severe cases with substantial comorbidity.

In general practice, up to 25% of patients have co-occurring depression and anxiety. While primary care both in rural and non-rural areas recognizes both disorders, there’s frequently a gap in therapy, meaning they receive inadequate care of one or more conditions. Individuals that suffer from depression or anxiety are most likely to exhibit physical problems than symptomatology and mental health problems may first look generic and vague.

RELATIONSHIP BETWEEN DEPRESSION AND ANXIETY

When depression and anxiety are combined:

- are harsher,
- more likely to result in suicide,
- more incapacitating,
- more resistant to therapy,

- And affect mental, physical, social, and occupational functioning more than either disorder alone.

Stress and depression illnesses rank among the most prevalent mental health issues. Because of their frequent co-occurring conditions, these diseases are collectively referred to as internalizing diseases. In light of information obtained originating from the Mental Health and Services for Substance Abuse

Major depressive illness was expected to be present for 12 months in 7.1% of adults and 13.3% of adolescents in 2017, according to the administration. Despite the fact that there are few recent data regarding anxiety disorders, approximations for their 12- predominance of month in adulthood from 2001 to 2003 were 19.1%, and estimates for their lifetime prevalence in teenagers from 2001 to 2004 were 31.9%. In women, anxiety and depression disorders are more prevalent during their reproductive years than in men, with a 2:1 ratio.

All mental illnesses have comorbidity, with depression and anxiety disorders ranking highest blatant instances of these illnesses and their symptoms. A worldwide assessment indicated that 45.7% of people suffering have a history of anxiety issues in addition to having severe depression at some point in their lives. These conditions typically coexist over the same time period, as evidenced by the fact and within the same 12-month period, 41.6% of people with serious depression also experienced one or more anxiety disorders. Studies on anxiety disorders indicate that patients with panic disorder (PAN) have a 50% lifetime comorbidity rate with depression, and individuals suffering from social anxiety disorder (SAD) have a comorbidity rate with fear estimated to be between 20% and 70%. (18), 48% of people with PTSD and 43% of those with generalized anxiety disorder, respectively, are affected by these conditions. The well-known Alternatives to Sequential Treatment to Alleviate provided the data.

The According to the Depression (STAR*D) study, 53% of patients with major depression also showed significant anxiety, which led to their classification as having an anxious depression.This shows comorbidity at the symptom level. Research suggests that internalizing diseases share a genetic risk, and that approximately 40% of depression and anxiety disorders have a moderate heritability. Major depressive disorder and generalized anxiety disorder appear to carry the highest hereditary risk among internalizing disorders.

Among the most prevalent diseases are anxiety and depression disorders in primary care and the general population. Depression and anxiety disorders often co-occur, and individuals with depression often display signs of both conditions. The two illnesses may occur simultaneously and meet the requirements. It can be difficult to differentiate between them, but both illnesses must be identified and treated because they have a notable correlation with both morbidity and death. The role of general practitioners allows them to recognize and treat mental health disorders in order to enhance outcomes.

What is fear?

Uncertainty is the conclusion of stress and worry, if they are the symptoms. Worrying and stress are two cognitive and physiological aspects of anxiety, so we feel it in both our minds and our bodies. In some respects, anxiety is what causes stress, Dr. Marques said, occurs when you are under a great quantity of worry and stress.

What causes anxiety?

Do you still recall that stress is a normal reaction to danger? Yet, there is no threat, thus worry is not the same thing.

Dr. Marques stated that anxiety can sometimes be a reaction to a false alarm, such as when you arrive at work and notice that someone is staring at you strangely. Since you're persuading yourself that your employer is mad at you or that your job might be in jeopardy, you start to experience all the physiological symptoms of a stress response. Your body is in a condition of fight or flight, the blood is rushing, but there is no predator lurking in the bushes.
However, there is a distinction to be made between having an anxiety disorder and simply feeling worried, which can be a normal aspect of daily living. A significant medical condition called an anxiety disorder can entail tension or worry.

DEPRESSION

SIGN -that profoundly impact a person's family, job, education, or interpersonal interactions. Anhedonia, weight gain or loss, depression, insomnia, or hypersomnia, exhaustion or lack of energy, compulsive thinking, depressive feelings, unwarranted guilt or remorse, helplessness and hopelessness, diminished cognitive function, social disengagement interactions, decreased Suicidal thoughts and sex urge are a couple of the signs and symptoms of depression. In cases of severe depression, an individual may experience hallucinations or, less frequently, delusions, which are typically unpleasant psychotic symptoms. Many somatic complaints including exhaustion, headaches, or stomach issues may be reported by a person who is sad.

Why people get depressed?

Although the specific etiology of depression is unclear, yet it's thought to be brought on by genetic problems, stressful events, environmental elements, or a mix of these and other unidentified reasons that result in chemical changes in the brain. Depression alters the neural circuits in the brain that regulate emotions, thought, sleep, eating, and behavior. It also throws off important neurotransmitters. Risk factors include women, a history of episodes or attempted suicide, co-occurring medical or drug use disorders, the passing of a close relative, an inadequate social support, among other troubling situations.



Fig. 1

TREATMENTS FOR ANXIETY MEDICATIONS

BRAND NAME	GENERIC NAME	CLASS	DAILY DOSAGE RANGE
Ambien	Zolpidem	Nonbenzodiazepine	5mg-10mg
Ativan	Iorazepam	Benzodiazepine	2mg-6mg
Buspar	Buspirone	Nonbenzodiazepine	15mg-60mg
Klonopin	Clonazepam	Benzodiazepine	0.5mg-4mg
Valium	Diazepam	Benzodiazepine	5mg-40mg
Xanax	Alprazolam	Benzodiazepine	0.5mg-4mg
Sonata	Zaleplon	Nonbenzodiazepine	5mg-10mg

TREATMENT FOR DEPRESSION

About 30% of those with depression are thought to seek medical attention, and of those who do, 30% or so actually experience remission. No adherence to drug regimens is one factor contributing to low remission rates. Before experiencing remission, many patients will need to go through numerous therapeutic iterations. Despite the possibility of clinical benefits within the first few weeks of therapy, it takes 3 to 4 weeks (and in rare cases 6 to 8 weeks) of consistent pharmaceutical use for the entire therapeutic effect to materialize. In situations when there is a high danger of injury to oneself or others, or where there is related self-neglect, hospitalization may be required

To reduce the likelihood of recurrence, following remission, typically, treatment lasts 16 to 20 weeks with a one-year continuation period being indicated. Since 2007, The FDA mandated the need for a black box alert. Describing the connection between the use of antidepressants and a higher danger of sociality in young adults, teenagers, and children to be included on all antidepressants sold in the United States.

TREATMENTS FOR DEPRESSION MEDICATIONS

CLASS	DRUGS
SSRIs	Citalopram, fluoxetine, escitalopram, sertraline, paroxetine, fluvoxamine,
SNRIs	Desvenlafaxine, Venlafaxine with duloxetine.
MAOIs	Isocarboxazid, selegiline phenelzine,
TCAs	Nortriptyline, imipramine, desipramine, doxepin, and amitriptyline.
MISCALLEANEOUS	Bupropion, mirtazapine.

HERBAL TREATMENT

Due to its widespread usage in Europe as a treatment for an excerpt from mild to severe depression from, or St. John's Wort (Hypericum perforate) is one of the most popular American botanical goods. Because the herb St. John's wort is becoming more and more popular in America and because there are questions regarding its effectiveness, the Health and Human Services (NIH) carried out a study in humans to ascertain whether a standardized extract of the herb was helpful while treating persons with moderately severe major depression.

WHY IS THIS ARTICLE BETTER THAN OTHERS?

Many research on the use of wearable technology and AI (Novel tool while organizing services for mental health to treat anxiety and depression have been published. Several reviews were done to summaries earlier investigations; but they possessed the following drawbacks. They initially, the focus was on wearable technology instead of wearable technology with AI. Secondly, their characterization of the wearable technology and AI models that were being used was incomplete. Thirdly, they only catered to specific age ranges, including young children and teenagers. Fourthly, they highlighted wearable technology to treat depression or anxiety as opposed to both. Finally, they failed to do relevant database searches, including those in MEDLINE, PsycINFO, IEEE Xplore, and ACM Digital Library. Lastly, they concentrated on wearable technology that only utilized ECG or electroencephalogram data for diagnostic purpose.

Thus, there has never been a greater the requirement for an evaluation that concentrates on wearable with AI pairing technology for melancholy and anxiety. This review's caliber ought to be on par with one that was previously done on wearable diabetic devices that were AI-paired. The objective of the current evaluation is to examine, certain theories useful and can be used to treat anxiety and depression and the characteristics of wearable AI for depression and anxiety in order to both assist consumers in making informed decisions and assist the scientific community in this area by locating holes and assessing potential the future directions.

THE PSYCHODYNAMIC THEORY OF DEPRESSION AND ANXIETY

Most theories of psychodynamics have concentrated the unconscious tensions people manifest as anxiety and depression symptoms. Sigmund Freud claimed that anxiety is a protective mechanism for suppressed and unconscious driving forces. The theory that discouraged people covertly harbor bad feelings toward the ones they love has also been considered by a number of psychoanalysts, leading to internalized indignation. This is the obstacle that Freud saw as preventing one from adjusting to emotions that are socially unacceptable. However, these psychodynamic theories have not received much experimental

BEHAVIOR THEORY OF ANXIETY AND DEPRESSION

Understanding how learned moral standards mitigate side effects through customary molding and highlighting, according to social scientists, induces regret and uneasiness. Essentially, the source of suffering sets apart disagreeable occurrences. Psychopathology is essentially assumed to be predetermined organically by the social model. Behavioral and cognitive therapies have proven to be a successful remedy for a wide range of Anxiety disorders include social anxiety disorder, panic disorder, phobias, and generalized anxiety disorder.(CBT). The premise behind CBT is that you may be able to manage your anxiety by examining your negative ideas and views to identify distortions.

THE REASONS BEHIND THE SHARP RISE IN COLLEGE STUDENTS' CONCERNS ABOUT THEIR MENTAL HEALTH

1. A dramatic transition that can be difficult to adjust to.
2. Increased academic pressure;
3. A rise in the frequency of anxiety and sadness in society
4. The quick development of technology and the deluge of information, especially on social media
5. Financial and economic strain
6. Unemployment related to food
7. The stigma around mental illness deters people from getting treatment; insufficient mental health education
8. There is a lack of skilled staff and overcrowding in college counseling centers.
9. The COVID-19 pandemic, which is expected to start in March 2020, has increased college students' stress levels. Pupils linked the epidemic to a number of factors, including anxiety and dread for their own and their loved ones' health, trouble focusing, disturbed sleep cycles, a decline in social relationships because of physical distance, and a rise in worries about their academic performance

INTERSECTIONALITY

Students in colleges have a diverse spectrum of identities and backgrounds. According to an inter sectionalist framework, individuals who identify with multiple historically marginalized groups social class, gender identity, color, religion, sex, (dis)ability, or sexual orientation, among other factors, may be subject to systemic inequality and/or disparities that reinforce one another. College students who identify as members of numerous marginalized groups may have particular difficulties that exacerbate or trigger symptoms of mental illness, making treatment access and utilization more challenging. According to earlier studies, those who experience prejudice are more likely to use drugs and alcohol as a coping mechanism. Throughout the continuum of care, practitioners and decision-makers on campus should take identity and campus climate into account when addressing mental health challenges.

PSYCHOLOGICAL TREATMENTS FOR MAJOR DEPRESSION

The most scientifically supported psychological treatment for depression is mental behavioral counseling (CBT).CBT is an approach that works well and is simple to use in hospital settings. The guiding ideas comprise providing education to patient, instructing them in fundamental relaxation techniques, and enhancing their capacity to recognize, confront, and modify maladaptive thoughts, emotions, perceptions, and actions. Reviews of systematic literature and meta-analyses have shown efficacy in treating depressed inpatients and those with long-term physical health issues. An organized analysis found that combining antidepressant therapy with no pharmacological interventions improved patient outcomes Depression treatments that are psychological in nature are covered in greater detail elsewhere in this supplement.

ANXIETY DISORDER PSYCHOLOGICAL TREATMENTS

Treatment suggestions for anxiety disorders are found in patient manuals and a practical practitioner guide Medications (odds ratio [OR]) favoring psychotherapy and active therapies versus controls, 0.32; 95% CI, 0.18-0.54) were reported to have comparable therapeutic outcomes for disorder of widespread anxiety.

UNIVERSAL DEPRESSION PHARMACOTHERAPY

The cornerstone of treatment for unipolar depression is antidepressant medication, which mainly acts on serotonin, noradrenaline, and dopamine receptors in the central nervous system. The Better Access initiative's launch may have contributed to a rise in depression awareness as antidepressant prescriptions in general practice have grown recently. Some authorities are against the use of antidepressant mixtures since they may increase side effects without necessarily offering therapeutic benefit. Normalizing endogenous circadian rhythms is becoming increasingly important in the management of depression and anxiety. Bipolar disorder-related

CASUAL PATHWAYS

Developmentally, the primary issue is anxiety disorders, which almost often begin in infancy or adolescence. concurrent The main explanations for anxiety and depression are either hereditary predispositions to both disorders or the possibility that one illness is an epiphenomenon of the other .Increases in corticotrophin- cerebrospinal fluid release factor have been associated with both anxiety and depression; however, the way The hypothalamic-pituitary-adrenal axis regulates other peptides or hormones. Differs between the two conditions. In more recent times, depression and disorders related to it have been linked to oxidative, nitrosamine, and neuroinflammatory pathways. A psychosocial stressor typically occurs immediately following an individual's initial depressive episode. After three or more incidents, the likelihood that more will happen on their own rather than as a result of an external incident increases.

TRADITIONAL TREATMENTS

1. **Diathesis-Stress Models of Depression**

The model will direct our discussion. According to Monroe and Simons' (1991) diathesis-stress paradigm, there are two universal elements that affect when depression first appears. A bad life event is one of these components. (Or a cause of conflict). Typically, a significant source of affection, stability, personality, or self-worth is lost during these incidents. The passing of a friend or relative, the breakup of a meaningful emotional connection, or notable Individual shortcomings are instances of prototypic events. (Arieti and Bemporad, Hopelessness and worthlessness are two self-relevant characteristics of depression. Mourning and Melancholia, a book about depression written by Sigmund Freud, was published in 1917.

Freud claimed that downturn can have two structures, among other things. With mourning, Depression is a painful reaction to losing a real love object, such as a friend or family member. Unusual depression and depression are depicted as symptoms of grief, but not guilt, shame, or regret. Depression is a reaction to the absence of an increasingly mental nature (such as a seeming inability to follow one's own rules or goals). Extreme despair, self-blame, and isolation from others are all used to define it. Expanding on these themes, modern analysts have identified two self-significant distinctions typically present in depression. When people realize there is nothing they or anyone else can do to prevent an undesirable outcome or attain an ideal conclusion, they become depressed.

Depression produces depressive and denunciative feelings, which are important components of depression. When people believe they are weak, corrupt, or just generally lacking or flawed, they feel useless. These acknowledgments are also obvious highlights of despair. One of these distinctions can sometimes be used to characterize sorrow (a person may feel miserable but not useless in the wake of a friend or family member's demise, for example). Many occasions, the two judgments are available (when a friend or family member passes away, people may feel sad that they will never see the person again and guilty about not doing enough to honor the person's memory)

Furthermore, wretchedness is usually linked to defenselessness. This expression refers to the notion that an unwanted circumstance cannot be changed. Vulnerability has a kind called depression. Though by definition unhappy people also feel vulnerable, people might feel powerless without being depressed (e.g., I have no alternative options, but I know someone who does). Furthermore, being helpless can result in being useless. Feelings of weakness may make some people feel even more helpless.

2. DEPRESSION'S PROGRESSION

As we analyse research on self-applicable techniques in depression, burdensome reactions and depressive episodes serve as another reminder. A portion of our job will involve auditing reasons why individuals have an instant burdensome response to a situation; alternative investigation aims to comprehend why a burdensome reaction persists into a protracted burdensome scenario. This qualification is necessary since discouraged reactions to unfortunate and unsatisfactory circumstances are actually quite common. However, most of these reactions are self-restraining and tend to subside after a few days or weeks. A small percentage of the time, these reactions persist or intensify and cause actual disruptions to daily life. Sadly, the distinction between momentary distressing Depression researches does not always sustain responses and clinically meaningful depressive episodes.

In certain research, the phrase "discouraged members" is used to describe individuals who are experiencing only temporary or mildly burdensome reactions to an incident. These answers, which are frequently estimated without any other report, are not really equivalent to increasingly outrageous or burdensome scenes (for discussions of this issue refer to Kendall, Hollon, Beck, Hammen, and Ingram, 1987; Flett, Vredenburg, & Krames, 1993; Kendall, Hollon, Beck, and Hammen, 1997; and Vredenburg, Flett, and Krames, 1993. To minimize any confusion, I will refer to assessment with members who have not received a clinical diagnosis of depression using the term dysphoria rather than depression.

PSYCHOANALYTIC MODELS,

Researchers operating within the psychoanalytic convention were the ones who initially developed self-worth possibilities models of depression. According According to Fenichel (1945) and Rado (1928), depressed people have overly high demands for interpersonal support. When they don't receive the approval and comfort they really want from others, despair sets in. The situation is very similar to that of a small child who longs for the constant, unwavering attention, and warmth of others. People who require a lot of relationship reliance are seldom given due consideration.

When these requirements are confused, as they definitely will be, the effectively low level of confidence, which lacks important other resources to support it, is also lowered, which leads to depression in its clinical form. According to Hirschfeld, Klerman, Chodoff, Korchin, and Barrett (1976), page 384 In order to address more factors of self-worth, Bibring (1953) broadened the scope of this study. Bibring distinguished three categories of self-goals frequently held by depressives based on his clinical experience.

According to Strauman (1989; Strauman and Higgins, 1987), inclined persons should be: admired, acknowledged, appreciated, and esteemed; overstated; substantial; competent; effective; and unnecessary; acceptable; cherishing; moral; and upright. According to Bibring, people with these heightened beliefs experience discouragement when they acknowledge that they are already falling short of these requirements and won't have the opportunity to see them again. In essence, people give up faith because they believe they don't comprehend their objectives. Take note at this point of how this model combines elements of despair (the belief that one would always fall short of one's ideals) and uselessness (insufficiency).

3. ANXIETY SELF-HELP

Not everyone who experiences severe stress suffers from anxiety. You could feel tense due to a plan that is too demanding, an inadequate rest or exercise, strain at home, or other factors, labor or even from drinking too much coffee. Most essential, whether or not In reality, you suffer from an anxiety problem, if your way of life is bad and distressing, you're likely to feel restless. These suggestions can help reduce anxiety and manage the negative effects of confusion: Connect with other people

While addressing Meeting your concerns in person usually helps them to seem less daunting. Depressing and confined situations can also frequently cause or worsen uneasiness. Make it a point to routinely get together with friends, sign up for a support or self-improvement group, or talk to a loved one you can confide in about your issues. If, by chance, you don't know anyone, it's never too late to make a connection. form a network of people who are supportive and make new acquaintances

4. Manage your stress

If you're experiencing extreme anxiety, the Stress Board might be able to assist. Look over your tasks and decide which ones you can refuse, forgo, or assign to others. Practice calming techniques. Regular use of relaxation techniques can lessen anxiety symptoms and boost happy, optimistic sentiments of wealth. Examples of these techniques include deep breathing, dynamic muscle relaxation, and care contemplation. Regular exercise-A common pressure-buster and anxiety-reliever is exercise. Focus on at least 30 minutes of oxygen-consuming activities per day to achieve the best benefit. Exercises that require you to move your arms and legs in time to music are particularly fascinating. Try walking, running, swimming, hand-to-hand combat or other forms of movement.

THEORIES OF TREATMENT FOR ANXIETY AND DEPRESSION (BOTH)

1. Depression's Helplessness Theory

By creating the academic theory of depression's "defenselessness hypothesis," which maintains that people who experience repeated injuries or Depressive episodes are then caused by upsetting interactions and the perception that their circumstances are irrational, Seligman

(1965) changed the psychological perspective. According to the updated theory, people blame internal, external, and consistent sources for unfortunate life situations. Moreover, these people are said to have an opposite attribution style that inspires grief. The reformulated theory emphasizes how several circumstances interact to generate a subtype of mourning called as learned weakness and falls under the psychological diathesis-stress family. Stressful life experiences have been linked to anxiety and depression in studies, suggesting that many clutters could stem from a particular mental shortcoming.

Psychodynamic Theory of Depression and Anxiety

Most psychodynamic theories have concentrated on the unconscious tensions that people manifest as anxiety and depression symptoms. Concern was seen by S. G. Freud as a defense mechanism for a passive, unaware driver Impulses. The theory that discouraged people privately feel bad about the people they care for makes anger internal has also been considered by several psychoanalysts. This is the obstacle that Freud saw as preventing one from adjusting to emotions that are socially unacceptable. Unfortunately, these psychodynamic theories have not received much experimental support.

The Behavior Theory of Depression and Anxiety

Social scientists think that understanding how learned behavioral norms might be applied to mitigate negative effects by techniques like exhibiting historical molding. The etiology of suffering, in short, makes a distinction between painful experiences. Psychopathology is essentially assumed by the social model to be predetermined organically.

2. **Freud's Anxiety Theory**

Freud was among the first to emphasize the significance of discomfort and made a distinction between goal anxiety and hypochondriac anxiety. Target anxiety, sometimes known as dread, was regarded by Freud as a rational feeling and a normal response to a threat. He perceived insanity as an unconscious internal conflict in the person because the conflict was unconscious and the person didn't realize what was causing their concern. Just as there are different degrees of concern, there are different degrees of familiarity with what's causing someone to feel uneasy. Bennett (1982)

Analytical Theory Sigmund Freud's commitments to the definition of unease were creative and reassuring, but to an extent ambiguous. The fact that Freud's perspective underwent significant revision roughly 30 years after the analysis's founding causes some of the ambiguity. (Levitt, 1967). The Problem of Anxiety is where Freud presented his fresh viewpoints. Anxiety is a specific state of discomfort accompanied by an engine release along several channels, which is a symptom of danger. Freud distinguished between three different types of unease, each with a unique source or motivator. Genuine or target anxiety had an external cause and was truly associated with the threat posed by the feared thing, circumstance, or person. Physiological thrill and feelings of dread were also used to explain hypochondriac worry, but the source of danger was the individual's own inner desires rather than an external event prevent corrosive driving forces. When mental defenses failed to stop the undermining of driving forces mindfulness, masochist unease was felt.

Masochist worry typically has a basis in the fact that the world, as perceived by parents and other experts, rejects it, the child's penchant for rash actions (Hall and Lindzey, 1957). Fear of the inner voice is moral distress. A person with a strong superego will typically experience intense regret when he plans to violate previously established moral rules. However, moral fear

also has a rational foundation because the person has already experienced rejection for violating the moral norm in the past

3. **Neo-Freudian Anxiety Theory**

   Neo-Freudian writers like Harry Stack Sullivan, Karen Homey, and Erich Fromm have all written eloquently about the concept of anxiety. One could argue that Neo-Freudians put more emphasis on the importance of social, ecological, or societal variables in determining character and downplayed the role of organic and instinctual aspects.

   As stated by Levitt (1967), socialization begins once the foundational component of self-image has been established. By using measures for discipline and the risks of losing support, guardians enforce social mores and virtues without relying on a clear articulation of driving forces. This threat to dependency needs causes anxiety and motivates the child to comply with guardians' wishes in order to reduce unease. As a result, those whose formative years were spent largely in conflict would be more anxious about the future. Sullivan's stance is unequivocal.

   The person who is creating is continuously anxious "I should have or do this, but in this manner or having, I should not acquire your dissatisfaction with my being," is a saying regarding one fundamental issue: the sufficient human accomplishment of need fulfilment. Sullivan agreed that large anxiety levels affected a person's ability to meet his requirements, disrupted interpersonal relationships, and caused confusion in speculative thinking. Additionally, Sullivan stated that one of the amazing tasks of brain research is to discover the fundamental sources of anxiety in interpersonal relationships (Hall and Lindzey, 1957). Neo-Freudians agreed that anxiety began during the socialisation period and that it cannot appear before the child is aware of his condition

4. **Learning the Anxiety Theory**

   The learning hypothesis attempts to test, to some extent, provisional psychoanalytic norms. It's possible that Dollard and Miller's (1950) description of the destinations of learning scholars was generally remarkable. Drives are the term for motivational forces in the learning hypothesis. The three primary urges are lust, hunger, and yearning. Through the learning process, increasingly compelling desires are generated or acquired while the creature is present. Support and punishment, or compensation and discipline, intervene in the securing of drives. (Levitt, 1967). Anxiety is a fantastic auxiliary drive, according to Dollard and Miller. This intellectual drive is based on an innate need to avoid suffering. People who have experienced more feelings of dread are therefore likely to be more prone to unease in the future, primarily because to the norm of upgrading conjecture. In any event, this directive has been taken into account. According to an assessment of studies on the role that job discomfort plays in learning, According, to Murray (1969), persistent worry is unrelated to improvement theory.

5. **Anxiety: A Physiological Theory**

   No anxiety hypothesis should ignore physiological signs of unease. May (1950) devoted a portion to the natural understanding of unease with a focus on Kurt Goldstein's comprehensive hypothesis and method. (1959). According to Goldstein, if we observe someone in a state of unease, we can see distinctive real changes such as specific facial and body expressions, specific physiological conditions, engine wonders, changes in heart rate, and vasomotor changes, among other things. We most certainly have no reason to discount these developments from a study of the wonder of anxiety. Further expressing suppositions, Funkenstein et al.

(1957) distinguished between the physiological effects of anger and anxiety. The physical, an epinephrine-like response is associated with anxiety, whereas a norepinephrine-associated response is associated with anger. Funkenstein specifically observed that in dread and anxiety, pulse, palmar conductance, and respiration rate increased more than in frustration.

CURRENT TRATMENTS FOR ANXIETY

Benzodiazepines: Due to their sedative effects, they have a soothing impact, An Alprazolam, A clonazepam, Etizolam.

Neurotransmitters are affected by antidepressants, which alleviate the symptoms. The drug citalopram. The drug Fluoxetine, Sertraline

MECHANISM OF ACTION OF CLONAZEPAM

Clonazepam is one of the most useful 1, 4-benzodiazepines for managing certain different myoclonus kinds. Its main method of action is directly interacting with benzodiazepine receptors to stimulate GABA ergic transmission in the brain. Clonazepam is a very strong benzodiazepine with a long half-life. It works on GABA-A receptors as a positive allosteric modulator to provide pharmacological effects. The natural ligand of the ligand-gated chloride ion-selective channel known as the GABA-A receptor is gamma-amino butyric acid, or GABA. Benzodiazepines (BZDs) diminish neuronal excitability by increasing the frequency of chloride channel opening, which causes the neurons to become hyperpolarized and fire less frequently. This results in an increase in GABA-A activity and relaxation of the brain.

The brain and limbic system contain large amounts of the neurotransmitter GABA. GABA receptors come in three subtypes: A, B, and C. BZDs, however, only affect GABA-A receptors. Each receptor complex consists of two alpha, two beta, and one gamma subunits. Additionally, they have one BZD-binding site and two GABA-binding sites. BZD-binding sites are located at the interface between the alpha and gamma subunits of the receptor complex, and they are not attached to the same receptor site as the endogenous neurotransmitter GABA. GABA-A receptors interact to cause a conformational shift in the chloride channel of the receptor, which hyperpolarizes the cell and causes GABA to have an inhibitory effect on the central nervous system.

The isoforms of the alpha subunit of GABA receptors further split them into several BZD receptors. Benzodiazepine type-1 receptors (BZ1), which are made up of alpha-1 subunits and are widely distributed in the brain, thalamus, and cerebellum, are known for their anticonvulsant and sedative properties. While the calming effects of BZDs are mediated by benzodiazepine type-2 receptors with alpha-2 subunits, which are mostly found in the limbic system, motor neurons, and dorsal horn of the spinal cord

MECHANISM OF ACTION OF BENZODIAZEPINES

Benzodiazepines like clonazepam (Klonopin), lorazepam (Ativan), and alprazolam (Xanax) have an impact on the brain and central nervous system (CNS). They fall into one of three pharmacological categories: moderate tranquillizers, sedative-hypnotics, or GABAergic medications.

The way benzodiazepines work is by making the GABA (gamma-aminobutyric acid) receptor more active. The sedative, hypnotic (sleep-inducing), anxiolytic (anti-anxiety), anticonvulsant, and muscle relaxant effects of the medications are the consequence of this.

FIG -MECHANISM OF ACTION OF BENZODIAZEPINES



CURRENT TREATMENTS FOR DEPRESSION

Selective serotonin reuptake inhibitors, or SSRIs, are the most commonly given drugs for depression at the moment. Among the brand names that are frequently prescribed include Prozac (fluoxetine), Paxil (paroxetine), Zoloft (sertraline), Celexa (citalopram), and Luvox (fluvoxamine). The negative effects of SSRIs are typically less severe than those of other antidepressant groups.

BUPRON/DEXTROMETHORPHAN

MAJOR DEPRESSIVE DISORDER AUVELITY AUVELITY: Due to its distinct oral NMDA antagonist mechanism, quick antidepressant efficacy in controlled studies and clinical trials, and generally good safety profile, Auvelity's approval marks a significant advancement in the treatment of depression, according to Maurizio Fava, MD, chief psychiatrist at Massachusetts General Hospital in Boston. Considering the crippling severity of depression, Auvelity's effectiveness as demonstrated at one week and sustained thereafter could drastically change the present paradigm for treating this disorder. The company states that over 1100 MDD patients participated in comprehensive clinical trials for the medication.After six weeks of comparison between Auvelity and a placebo, the study found that Auvelity significantly reduced symptoms of depression when compared to bupropion sustained-release tablets.

Auvelity (105 mg) contains a combination of dextromethorphan (45 mg), an N-methyl-d-aspartate (NMDA) receptor antagonist, and bupropion, an inhibitor of norepinephrine-dopamine reuptake. Auvelity's unique mechanism of oral NMDA antagonists, rapid antidepressant effectiveness, and manageable risk profile make it a revolutionary step in the treatment of depression. Further research is necessary to determine Auvelity's effectiveness and efficiency in treating patients with MDD and comorbidities.

Because of its innovative oral NMDA antagonist action, quick antidepressant efficacy, and manageable risk profile, Auvelity is a ground-breaking drug for depression. Additional investigation is required to ascertain the effectiveness and efficiency of Auvelity in treating individuals with comorbidities and major depressive disorder.



FIG 2.

WHY AUVELITY IS BETTER

According to Retired clinical psychologist and medical psychologist Joseph E. Comaty, PhD with a prescription drug licence in Louisiana, "the main benefit demonstrated in the clinical trials is faster onset of action." therapeutic psychopharmacology was Dr. Comaty's main area of study, with a particular emphasis on the therapeutic management of the three main mental disorders: bipolar disorder, major depressive disorder, and schizophrenia. "After one week of treatment, Auvelity showed improvement in depression rating scale scores compared to placebo. Current antidepressant therapies typically take several weeks to produce a response. Ketamine is the only other depression medication that has been proved to work as soon as Auvelity.

DEPRESSION-ZOLOFT

ACTION TIME-Many patients report and improvement in their symptoms within the first two weeks. Zoloft works by balancing serotonin levels in the brain and nerves feeling emotionally numb increased sweating, indigestion.

ALZHIMER-GALANTAMINE

ACTION TIME -Many patients report an improvement in their symptoms within four weeks. It enhances the intrinsic action of acetylcholine on nicotinic receptors nausea, vomiting, diarrhea, loss of appetite; weight loss Auvelity demonstrated rapid and sustained symptom improvement across multiple scales.

ONGOING HUMAN TRIALS FOR GENERAL ANXIETY DISORDER INVOLVE LSD COMPOUND-RECENT

According to MindMed, the first patient in the phase 2b dose-optimization trial for MM-120 for the treatment of generalised anxiety disorder (GAD) received a dose of a pharmaceutically optimised form of lysergic acid diethylamide (LSD). (95)

"The start of our phase 2b clinical trial, the largest well-controlled LSD clinical trial ever conducted, represents a significant milestone for MindMed and the many patients suffering from GAD," said Robert Barrow, MindMed's Chief Executive Officer and Director.

"This exciting next step in the advancement of LSD builds on the positive topline data presented by our partners at University Hospital Basel in May 2022, which demonstrated the rapid, long-lasting, and statistically significant effects of LSD and its potential to safely alleviate anxiety and depression symptoms." The results of our phase 2b trial will guide the dose selection and development strategy for our pivotal phase 3 clinical trials, as we continue our efforts to bring a new potential treatment to the millions of people living with GAD."

This multi-center, parallel, randomized, double-blind, placebo-controlled investigation is called the phase 2b experiment. Two options will be offered to the 200 participants in the study: a placebo or up to 200 g of MM-120 given once. Contrasting the drop in symptoms of anxiety four weeks after taking one MM-120 injections among the five treatment groups is the main objective. Quality of life and safety assessments are significant secondary goals that can be evaluated up to 12 weeks following the single dosage.

arlier this year, the American Psychiatric Association released an official statement on psychedelics that encouraged this kind of research: "There is currently insufficient scientific evidence to support the use of psychedelics to treat any psychiatric disorder except within the context of approved investigational studies." "The American Psychological Association supports continued research and therapeutic discovery into psychedelic agents with the same scientific integrity and regulatory standards as other promising therapies in medicine." (96)

Researchers examined lysergic acid diethylamide (LSD) between the 1950s and the 1970s to assess personality and behavioral changes, as well as the alleviation of mental symptoms in a range of medical conditions. LSD was applied to treat psychosomatic disorders, addiction, anxiety, and depression. Nonetheless, most of the study was conducted in an outdated manner, and it took several decades for interest in LSD research and its potential therapeutic benefits for psychiatry to reemerge.

Finding randomized, controlled clinical trials that evaluate the potential benefits of LSD therapy in psychiatry is the goal of this project.

LSD Trials Are Reporting A Little Less Tripping, and A Lot Less Anxiety

Lauderdale, Lauderhill a particular kind of LSD is being researched in hopes of helping treat generalized anxiety disorder.

Segal Trials researchers are conducting a large randomised trial to investigate the compound m-m-120, also known as LSD D-tartrate.

I genuinely think that these drugs, such as mm120 LSD, will fundamentally alter our understanding of anxiety," stated Dr. Rishi Kakar, Chief Scientific Officer and Medical Director of Lauderhill's Segal Trials.

While receiving treatment, every study participant is kept under surveillance for a number of hours. The study is not open to participants who have had psychosis or seizures in the past.

Roughly 6% of adults will at some point in their lives experience generalized anxiety disorder, a chronic and frequently incapacitating mental health condition.

Furthermore, a new study demonstrates that a low-level electrical current device is more successful in identifying lymphedema in breast cancer patients following radiation therapy or surgery.

According to Dr. Chirag Shah of the Cleveland Clinic, "Lymphedema can really cause discomfort and loss of function; women may have difficulty lifting their arm or using their hand." It can also result in lymphangitis, a secondary infection of the arm that can significantly affect one's quality of life and mental health.

TRIALS WITH LSD SHOW LESS ANXIETY

Everyone is familiar with the television ad from the early 1990s that simply stated, "This is your brain. Your brain is drugged up in this." To represent the before and after consequences of drug usage, the actors in the commercial used everything from fresh eggs to ground beef. Although it was enjoyable, it didn't truly explain how drugs affected the brain.

A scrambled egg obviously couldn't be my brain, can it? Hallucinogens like LSD and its effects on the human brain are now being studied by researchers. Many people have seen before and after photos showing everything from impaired motor function to holes developing in the brain as a result of protracted drug usage. Scientists studied how medications affected people with mental illness in the early 1950s and 1960s.

KEY WORDS

RECENT STUDIES ON HOW DANGEROUS ANXIETY AND DEPRESSION ARE FOR EVEN CHILDRENS

The "gold standard" for evidence-based preventive therapies for internalizing issues in young children (ages 0–8 years) has been determined to be randomized controlled trials.standard' way to evaluate the success of programmes. The review made clear that, in contrast to the substantial body of evidence that exists for child behaviour (externalizing/conduct) issues, internalising problems were the focus of relatively few preventive interventions.

Early Start had the greatest overall balance of evidence for reducing infant internalising issues when it came to interventions starting infancy. In New Zealand, the Early Start programme focuses on providing one-on-one house visits to stressed-out and at-risk mothers over the course of two to three years. All families were screened for risk by primary care services, and after completing five weeks of training, family support specialists were scheduled to make weekly home visits. In one randomized trial assessment with a three-year follow-up, it was discovered that Preschool attendance, family interactions (including abuse), and internalizing difficulties in children were all improved by this intervention. The strongest combination of evidence for reduction was found in two programsg internalising issues when interventions started at a young age. In a controlled study involving parents of kids with behavioural issues, it was discovered that a short (three-month) psych educational group-based programme in Canada also decreased kids' anxiety. But this trial's wait-list control strategy suggests that it is unknown whether the programme will be effective after a few weeks. The three-month-long Cool Little Kids programme in Australia is geared towards parents of temperamentally reserved pre-schoolers; two randomised trial assessments with follow-up at six months and three years revealed the programme was successful in preventing internalising disorders in children. Parents of preschool-aged children with temperamental inhibitions were asked to take part in parenting groups that met every two weeks for 1.5 hours and were led by a clinical psychologist as part of the Cool Little Kids trials.

This programme focuses on child inhibition and overprotective parenting and tries to increase pre-schoolers' resilience in the face of troubling worries and situational fears. It teaches parents how to reduce their own and their preschooler's worry and suffering. (If applicable). According to the first experiment, By the time they were five years old (50% vs. 64%), intervention children had significantly fewer anxiety problems than controls; by the time they were seven years old (40% vs. 69%), these benefits were even more pronounced.The program considerably reduced the anxiety disorders of preschool-aged children (53% intervention vs. 93% controls), according to the second trial, which concentrated on parents with anxiety disorders. As a result, Cool Little Kids is the first and, for the time being, the only early childhood internalization prevention program accessible. Leading the way in early intervention research is Cool Little Kids.

In the area, with an emphasis on anxiety Long-term For relatively short-term prevention programmes like Cool Little Kids, it is necessary to gather effectiveness data (over more than 5 years), which calls for adequate study funding. Evaluation of the programme's efficacy across big population representative samples is another challenge. A population-level randomised trial is presently being conducted to examine the feasibility of routinely screening "at risk" children (temperamentally-inhibited) by using this intervention and a global preschool service platform. Moreover, few studies have assessed the financial benefits of early mental health intervention initiatives for kids. The expenses of implementation services (training, program materials, provider remuneration), as well as costs to families, could be included in these evaluations. (loss of earnings, transportation expenses), and future health and welfare expenditures averted by implementing an early intervention.

Research on identifying depression in preschoolers and creating innovative early intervention programs are still in their infancy. A recent analysis of initiatives to prevent childhood depression did not find evidence that depressive disorders can manifest as early as preschool age, such young toddlers are included. Parent-Child Interaction Therapy has recently undergone its first round of pilot testing as a possible early intervention for depression in pre-schoolers.

The urgent need for developing and accessing psychotherapeutic interventions is highlighted by the lack of treatment programmes for depression in young children and by rising rates of children being given antidepressants with unclear efficacy. Since the 1990s, there has been a growing understanding that internalising issues in early children, such as anxiety and depression, can have crippling consequences if they last for an extended period of time. Known risks for internalising issues in young infants include both inherited and environmental factors.(For example, temperamental restraint in children, anxiety or melancholy in parents, and harsh or overly protective parenting).

A body of research supporting prophylactic early intervention programmes for young children who are anxious or depressed is beginning to emerge. The current body of research on preventative intervention for young children's internalizing problems is still very modest, compared to thirty years of research on early intervention for behavior (conduct) problems. It is vitally necessary to conduct more study on early prevention of anxiety and (especially) depression. The Cool Little Kids parenting programme has the strongest proof to date supporting its effectiveness in treating anxiety. The concision, focus, and proof that it prevents later anxiety disorders are all benefits of this programmer

DISCUSSION

This article's goal is to give a general summary of the major depressive and anxiety disorders introduction, linkages and goals between both and their various treatments, research difficulties and goals, with different ideas of treatment for anxiety and depression for all age groups.

ALL THEORIES AND NEW TREATMENTS WERE DISCUSSED IN THIS ARTICLE

HERBAL TREATMENT	PSYCHODYNAMIC THEORY OF ANXIETY AND DEPRESSION
potential causes of the recent increase in mental health concerns among college students	behavior theory of anxiety and depression
anxiety disorder psychological treatments	psychological treatments for major depression
Intersectionality	unipolar depression pharmacotherapy
onal treatments	sis-stress models of depression
psychoanalytic models	anxiety self help
theories of treatment for anxiety and depression	psychodynamic theory of depression and anxiety
or theory of anxiety and depression	freud's anxiety theory
reudian anxiety theory	learning the anxiety theory
anxiety: a physiological theory	depression's progression
depression's helplessness theory	current treatments for depression
t treatments for anxiety	auvelity new invention
ıg human trials for general	y disorder involve led compound recent

CONCLUSION

In general practice, up to 25% of patients experience co-occurring anxiety and depression. Condition screening is crucial because certain individuals are more likely to abuse drugs, react poorly to treatment, remain incapacitated longer, have more illnesses overall, and utilize health services more frequently. While there are effective therapies for some illnesses, there is a paucity of knowledge about managing co-occurring diseases such as depression and anxiety.

More than one-third of people with psychiatric disorders decide not to seek care, and nearly half of them receive therapies that may not be beneficial. This suggests that in order to enhance professional practise and promote better mental health outcomes, there is a need for greater public awareness and specialised training. The articles in this issue also provide a list of previous treatments for various illnesses, as well as present and prospective therapies in the future.

Additionally, developmental perspectives are provided, highlighting the role that early parenting plays in reducing depression risk, and age-related research plays a critical role in understanding how individuals with anxiety disorders perceive and respond to stressors. Regarding treatment, the papers present new ideas supporting more targeted prefrontal cortical TMS targeting in relation to various symptoms, discuss the advantages and disadvantages of age-specific interventions for people with anxiety disorders in children and adults, and provide data on the benefits and drawbacks of considering the use of psychedelics in therapy.

REFERENCE

Australian Bureau of Statistics. National Survey of Mental Health and Wellbeing: summary of results, 2007.

Hunt C, Issakidis C, Andrews G. DSM-IV generalized anxiety disorder in the Australian National Survey of Mental Health and Well-Being. Psychol Med 2002; 32: 649-659.

Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996-1997; 4: 160-168.

Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005; 66 Suppl 8: 22-29.

Gonçalves DC, Pachana NA, Byrne GJ. Prevalence and correlates of generalized anxiety disorder among older adults in the Australian National Survey of Mental Health and Well-Being. J Affect Disord 2011; 132: 223-230.

Regier DA, Rae DS, Narrow WE, et al. Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry Suppl 1998; (34): 24-28.

Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-627.

Sartorius N, Ustün TB, Lecrubier Y, Wittchen HU. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry Suppl 1996; (30): 38-43.

Jameson JP, Blank MB. Diagnosis and treatment of depression and anxiety in rural and nonrural primary care: national survey results. Psychiatr Serv 2010; 61: 624-627.

Goldberg D. Epidemiology of mental disorders in primary care settings. Epidemiol Rev 1995; 17: 182-190.

Substance Abuse and Mental Health Services Administration (SAMHSA): Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53). Rockville, Md, Center for Behavioral Health Statistics and Quality, SAMHSA, 2018.

Kessler RC, Chiu WT, Demler O, et al: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617–627, correction, 62:709

Merikangas KR, He JP, Burstein M, et al: Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication–Adolescent Supplement (NCSA). J Am Acad Child Adolesc Psychiatry 2010; 49:980–989

Kessler RC, McGonagle KA, Zhao S, et al: Lifetime and 12-month prevalence

of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8–19

Kessler RC, Sampson NA, Berglund P, et al: Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci 2015; 24:210–226

Dunner DL: Management of anxiety disorders: the added challenge of comorbidity. Depress Anxiety 2001; 13:57–71

KesslerRC,SonnegaA,BrometE,etal:Posttraumaticstressdisorderin the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52:1048–1060

Brawman-Mintzer O, Lydiard RB, Emmanuel N, et al: Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry 1993; 150:1216–1218

FavaM, Alpert JE, Carmin CN, et al: Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004; 34:1299–1308

Hettema JM: What is the genetic relationship between anxiety and depression? Am J Med Genet C Semin Med Genet 2008; 148C: 140–146

Australian Bureau of Statistics. National Survey of Mental Health and Wellbeing: summary of results, 2007. Canberra: ABS, 2007. (ABS Cat. No. 4326.0.)

Hunt C, Issakidis C, Andrews G. DSM-IV generalized anxiety disorder in the Australian National Survey of Mental Health and Well-Being. Psychol Med 2002; 32: 649-659.

Gonçalves DC, Pachana NA, Byrne GJ. Prevalence and correlates of generalized anxiety disorder among older adults in the Australian National Survey of Mental Health and Well-Being. J Affect Disord 2011; 132: 223-230.

Sartorius N, Ustün TB, Lecrubier Y, Wittchen HU. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry Suppl 1996; (30): 38-43.

Jameson JP, Blank MB. Diagnosis and treatment of depression and anxiety in rural and nonrural primary care: national survey results. Psychiatr Serv 2010; 61: 624-627.

Goldberg D. Epidemiology of mental disorders in primary care settings. Epidemiol Rev 1995; 17: 182-190.

National Institute of Mental Health. Depression. NIH Pub. No. 11-3561. Revised 2011. www.nimh.nih.gov/health/ publications/depression/ depression-booklet-pdf.pdf. Accessed October 5, 2011.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Publishing; 2000.

Tsuang MT, Faraone SV. The Genetics of Mood Disorders. Baltimore, MD: Johns Hopkins University Press; 1990.

Lewinsohn PM, Hoberman HH, Rosenbaum M. A prospective study of risk factors for unipolar depression. J Abnorm Psychol.

Nemeroff CB. Improving antidepressant adherence. J Clin Psychiatry.

Antidepressant use in children, adolescents, and adults. FDA. May 2, 2007. www.fda.gov/Drugs/DrugSafety/ InformationbyDrugClass/ UCM096273. Accessed October 5, 2011.

Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized, controlled trial. JAMA.

Welch V, Wy TJ, Ligezka A, Hassett LC, Croarkin PE, Athreya AP, et al. Use of mobile and wearable artificial intelligence in child and adolescent psychiatry: scoping review. J Med Internet Res 2022 Mar 14;24(3)

Elgendi M, Menon C. Assessing anxiety disorders using wearable devices: challenges and future directions. Brain Sci 2019 Mar 01;9(3):50 [FREE Full text]

Sequeira L, Perrotta S, LaGrassa J, Merikangas K, Kreindler D, Kundur D, et al. Mobile and wearable technology for monitoring depressive symptoms in children and adolescents: a scoping review. J Affect Disord 2020 Mar 15;265:314-324.

Lee S, Kim H, Park MJ, Jeon HJ. Current advances in wearable devices and their sensors in patients with depression. Front Psychiatry 2021 Jun 17;12:672347 [FREE Full text]

Juchems, PC. The use of wearable devices in the treatment and detection of anxiety: a systematic scoping review. University of Twente. 2022.

Yasin S, Hussain SA, Aslan S, Raza I, Muzammel M, Othmani A. EEG based major depressive disorder and bipolar disorder detection using neural networks:a review. Comput Methods Programs Biomed 2021 Apr;202:106007

Ahmed A, Aziz S, Abd-Alrazaq A, Farooq F, Sheikh J. Overview of artificial intelligence-driven wearable devices for diabetes: scoping review. J Med Internet Res 2022 Aug 09;24(8).

Pedrelli, P., Nyer, M., Yeung, A., Zulauf, C., & Wilens, T. (2015). College students: Mental health problems and treatment considerations. Academic Psychiatry, 39(5), 503-511.

Elzein, A., Shelnutt, K., Colby, S., Olfert, M., Kattelmann, K., Brown, O., ... & Mathews, A. (2017). The prevalence of food insecurity and its association with health and academic outcomes among college freshmen.

Son, C.,Hegde, S., Smith, A., Wang, X., & Sasangohar, F. (2020). Effects of COVID-19 on college students' mental health in the United States: Interview survey study. Journal of Medical Internet Research, 22, 1-14.

Crenshaw, K. (1989). Demarginalizing the intersection of race and sex: A black feminist critique of antidiscrimination doctrine, feminist theory and antiracist politics. University of Chicago Legal Forum, 1989(1), 139-167.

Hatzenbuehler, M. L., Corbin, W. R., & Fromme, K. (2011). Discrimination and alcohol-related problems among college students: A prospective examination of mediating effects. Drug and Alcohol Dependence, 115(3), 213-220.

Gerrard, M., Stock, M. L., Roberts, M. E., Gibbons, F. X., O'Hara, R. E., Weng, C., & Wills, T. A. (2012). Coping with racial discrimination: The role of substance use. Psychology of Addictive Behaviors, 26(3), 550-560.

Vu, M., Li, J., Haardörfer, R., Windle, M., & Berg, C. J. (2019). Mental health and substance use among women and men at the intersections of identities and experiences of discrimination: Insights from the intersectionality framework. BMC Public Health, 19(1), 1-13.

Fava GA, Ruini C, Rafanelli C, et al. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 2004; 161: 1872-1876.

Tiller JWG. Cognitive behaviour therapy in medical practice. Aust Prescr 2001; 24: 33- 37. http://www.australianprescriber.com/magazine/24/2/33/7 (accessed Sep 2012).

Cuijpers P, Clignet F, van Meijel B, et al. psychological treatment of depression in inpatients: a systematic review and meta-analysis. Clin Psychol Rev 2011; 31: 353-360.

Rizzo M, Creed F, Goldberg D, et al. A systematic review of non-pharmacological treatments for depression in people with chronic physical health problems. J Psychosom Res 2011; 71: 18-27.

Oestergaard S, Møldrup C. Improving outcomes for patients with depression by enhancing antidepressant therapy with non-pharmacological interventions: a systematic review of reviews. Public Health 2011; 125: 357-367.

Casey MF, Perera DN, Clarke DM. Psychosocial treatment approaches to difficult-totreat depression. MJA Open 2012; 1 Suppl 4: 52-5s5.

39 Andrews G, Creamer M, Crino R, et al, editors. The treatment of anxiety disorders: clinician guides and patient manuals. 2nd ed. Cambridge: Cambridge University Press, 2003.

Kyrios M, Mouding R, Nedeljkovic M. Anxiety disorders – assessment and management in general practice. Aust Fam Physician 2011; 40: 370-374.

Gonçalves DC, Byrne GJ. Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis. J Anxiety Disord 2012; 26: 1-11.

Therapeutic Guidelines Limited. eTG complete. 2012. http://www.tg.org.au/ index.php?sectionid=71 (accessed Sep 2012).

Chan HN, Mitchell PB, Loo CKA, Harvey SB. Pharmacological treatment approaches to difficult-to-tat depression. MJA Open 2012; 1 Suppl 4: 44-47.

Harrison C, Britt H, Charles J. Antidepressant use. Aust Fam Physician 2011; 40: 365.

Keks NA, Burrows GD, Copolov DL, et al. Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression? Med J Aust 2007; 186: 142-144.

Monteleone P, Martiadis V, Maj M. Circadian rhythms and treatment implications in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1569-1574.

Wittchen HU, Kessler RC, Pfister H, Lieb M. Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand Suppl 2000; (406): 14-23.

Middeldorp CM, Cath DC, Van Dyck R, Boomsma DI. The co-morbidity of anxiety and depression in the perspective of genetic epidemiology. A review of twin and family studies. Psychol Med 2005; 35: 611-624.

Boyer P. Do anxiety and depression have a common pathophysiological mechanism? Acta Psychiatr Scand Suppl 2000; (406): 24-29.

Maes M, Kubera M, Obuchowiczwa E, et al. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 2011; 32: 7-24.